| Year |
Citation |
Score |
| 2020 |
Geoffroy K, Bourgeois-Daigneault MC. The pros and cons of interferons for oncolytic virotherapy. Cytokine & Growth Factor Reviews. PMID 32694051 DOI: 10.1016/J.Cytogfr.2020.07.002 |
0.405 |
|
| 2020 |
Roy DG, Bell JC, Bourgeois-Daigneault MC. Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro. Biochemical and Biophysical Research Communications. PMID 32248971 DOI: 10.1016/J.Bbrc.2020.03.135 |
0.345 |
|
| 2019 |
Mullins-Dansereau V, Petrazzo G, Geoffroy K, Béland D, Bourgeois-Daigneault MC. Pre-surgical oncolytic virotherapy improves breast cancer outcomes. Oncoimmunology. 8: e1655363. PMID 31646102 DOI: 10.1080/2162402X.2019.1655363 |
0.352 |
|
| 2019 |
Martin NT, Roy DG, Workenhe ST, van den Wollenberg DJM, Hoeben RC, Mossman KL, Bell JC, Bourgeois-Daigneault MC. Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. Scientific Reports. 9: 1865. PMID 30755678 DOI: 10.1038/S41598-018-38385-7 |
0.342 |
|
| 2018 |
Bastin D, Aitken AS, Pelin A, Pikor LA, Crupi MJF, Huh MS, Bourgeois-Daigneault MC, Bell JC, Ilkow CS. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. Journal For Immunotherapy of Cancer. 6: 62. PMID 29921327 DOI: 10.1186/S40425-018-0366-2 |
0.365 |
|
| 2018 |
Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine. 10. PMID 29298865 DOI: 10.1126/Scitranslmed.Aao1641 |
0.315 |
|
| 2017 |
Aitken AS, Roy DG, Martin NT, Sad S, Bell JC, Bourgeois-Daigneault MC. Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 29293165 DOI: 10.1097/Cji.0000000000000208 |
0.314 |
|
| 2017 |
Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell AM, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, et al. Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. Cancer Research. PMID 29259007 DOI: 10.1158/0008-5472.Can-15-3308 |
0.348 |
|
| 2017 |
Aitken AS, Roy DG, Bourgeois-Daigneault MC. Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines. 5. PMID 28536346 DOI: 10.3390/Biomedicines5010003 |
0.32 |
|
| 2016 |
Galbas T, Raymond M, Sabourin A, Bourgeois-Daigneault MC, Guimont-Desrochers F, Yun TJ, Cailhier JF, Ishido S, Lesage S, Cheong C, Thibodeau J. MARCH1 E3 Ubiquitin Ligase Dampens the Innate Inflammatory Response by Modulating Monocyte Functions in Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 27940660 DOI: 10.4049/Jimmunol.1601168 |
0.575 |
|
| 2016 |
Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, et al. Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy Oncolytics. 3: 16027. PMID 27909702 DOI: 10.1038/Mto.2016.27 |
0.309 |
|
| 2016 |
Nagarajan A, Petersen MC, Nasiri AR, Butrico G, Fung A, Ruan HB, Kursawe R, Caprio S, Thibodeau J, Bourgeois-Daigneault MC, Sun L, Gao G, Bhanot S, Jurczak MJ, Green MR, et al. MARCH1 regulates insulin sensitivity by controlling cell surface insulin receptor levels. Nature Communications. 7: 12639. PMID 27577745 DOI: 10.1038/Ncomms12639 |
0.445 |
|
| 2016 |
Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC. Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity. Molecular Therapy Oncolytics. 3: 16001. PMID 27119116 DOI: 10.1038/Mto.2016.1 |
0.389 |
|
| 2016 |
Falls T, Roy DG, Bell JC, Bourgeois-Daigneault MC. Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. Ilar Journal / National Research Council, Institute of Laboratory Animal Resources. 57: 73-85. PMID 27034397 DOI: 10.1093/Ilar/Ilv048 |
0.315 |
|
| 2016 |
Veinalde R, Grossardt C, Bourgeois-Daigneault M, Kalle Cv, Jaeger D, Ungerechts G, Engeland CE. Abstract A068: Determinants of efficacy in cancer immunovirotherapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A068 |
0.409 |
|
| 2015 |
Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, et al. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell. 28: 210-24. PMID 26212250 DOI: 10.1016/J.Ccell.2015.06.009 |
0.325 |
|
| 2013 |
Bourgeois-Daigneault MC, Pezeshki AM, Galbas T, Houde M, Baril M, Früh K, Amrani A, Ishido S, Lamarre D, Thibodeau J. Tollip-induced down-regulation of MARCH1. Results in Immunology. 3: 17-25. PMID 24600555 DOI: 10.1016/J.Rinim.2013.02.002 |
0.638 |
|
| 2013 |
Bourgeois-Daigneault MC, Thibodeau J. Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase. Journal of Cell Science. 126: 989-98. PMID 23264739 DOI: 10.1242/Jcs.117804 |
0.586 |
|
| 2013 |
Finzi A, Perlman M, Bourgeois-Daigneault MC, Thibodeau J, Cohen ÉA. Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. Cellular Microbiology. 15: 809-22. PMID 23170932 DOI: 10.1111/Cmi.12074 |
0.576 |
|
| 2012 |
Thibodeau J, Bourgeois-Daigneault MC, Lapointe R. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology. 1: 908-916. PMID 23162758 DOI: 10.4161/Onci.21205 |
0.627 |
|
| 2012 |
Bourgeois-Daigneault MC, Thibodeau J. Autoregulation of MARCH1 expression by dimerization and autoubiquitination. Journal of Immunology (Baltimore, Md. : 1950). 188: 4959-70. PMID 22508929 DOI: 10.4049/Jimmunol.1102708 |
0.598 |
|
| 2011 |
Xiu F, Côté MH, Bourgeois-Daigneault MC, Brunet A, Gauvreau MÉ, Shaw A, Thibodeau J. Cutting edge: HLA-DO impairs the incorporation of HLA-DM into exosomes. Journal of Immunology (Baltimore, Md. : 1950). 187: 1547-51. PMID 21768396 DOI: 10.4049/Jimmunol.1100199 |
0.598 |
|
| 2011 |
Thibodeau J, Bourgeois-Daigneault MC, Lapointe R. Counteracting subversion of MHC class II antigen presentation by tumors Experimental and Applied Immunotherapy. 173-194. DOI: 10.1007/978-1-60761-980-2_8 |
0.591 |
|
| 2009 |
Gauvreau ME, Côté MH, Bourgeois-Daigneault MC, Rivard LD, Xiu F, Brunet A, Shaw A, Steimle V, Thibodeau J. Sorting of MHC class II molecules into exosomes through a ubiquitin-independent pathway. Traffic (Copenhagen, Denmark). 10: 1518-27. PMID 19566897 DOI: 10.1111/J.1600-0854.2009.00948.X |
0.633 |
|
| 2008 |
Thibodeau J, Bourgeois-Daigneault MC, Huppé G, Tremblay J, Aumont A, Houde M, Bartee E, Brunet A, Gauvreau ME, de Gassart A, Gatti E, Baril M, Cloutier M, Bontron S, Früh K, et al. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. European Journal of Immunology. 38: 1225-30. PMID 18389477 DOI: 10.1002/Eji.200737902 |
0.598 |
|
| 2008 |
Bourgeois-Daigneault M, Huppé G, Tremblay J, Steimle V, Thibodeau J. 144 Molecular mechanisms of MHC class II inhibition by the MARCH1 ubiquitin ligase in response to IL-10 Cytokine. 43: 269. DOI: 10.1016/J.Cyto.2008.07.186 |
0.585 |
|
| Show low-probability matches. |